MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 127349 | Name: MT-1207 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MT-1207 is a potent α1 and 5-HT2A receptor antagonist with remarkable IC50 in the picomolar level. Importantly, in the in vivo assay, MT-1207 achieved an effective blood pressure (BP) reduction in the 2K2C rat model without damaging renal function. MT-1207, with its significant advantages in terms of pharmacological effects, pharmacokinetic parameters, and a large safety window, was extensively investigated.

Chemical Structure

MT-1207 HCl
MT-1207 HCl
CAS#1610794-70-1

Theoretical Analysis

MedKoo Cat#: 127349

Name: MT-1207 HCl

CAS#: 1610794-70-1

Chemical Formula: C21H25ClN6S

Exact Mass: 428.1550

Molecular Weight: 428.98

Elemental Analysis: C, 58.80; H, 5.87; Cl, 8.26; N, 19.59; S, 7.47

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
MT1207; MT 1207; MT-1207; MT-1207 HCl; MT-1207 hydrochloride;
IUPAC/Chemical Name
3-(4-(4-(1H-benzo[d][1,2,3]triazol-1-yl)butyl)piperazin-1-yl)benzo[d]isothiazole hydrochloride
InChi Key
UFMLXCNESJKXFY-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H24N6S.ClH/c1-4-10-20-17(7-1)21(23-28-20)26-15-13-25(14-16-26)11-5-6-12-27-19-9-3-2-8-18(19)22-24-27;/h1-4,7-10H,5-6,11-16H2;1H
SMILES Code
N1(C2=NSC3=CC=CC=C32)CCN(CCCCN4C5=CC=CC=C5N=N4)CC1.Cl
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 428.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Xu TY, Wang P, Tian JS, Qing SL, Wang SN, Huang YH, Xu JY, Su DF, Liu JG, Miao CY. Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent. Acta Pharmacol Sin. 2021 Jun;42(6):885-897. doi: 10.1038/s41401-021-00636-1. Epub 2021 Mar 29. PMID: 33782540; PMCID: PMC8149631. 2: Vrettos NN, Wang P, Wang Y, Roberts CJ, Xu J, Yao H, Zhu Z. Controlled release of MT-1207 using a novel gastroretentive bilayer system comprised of hydrophilic and hydrophobic polymers. Pharm Dev Technol. 2023 Oct;28(8):724-742. doi: 10.1080/10837450.2023.2238822. Epub 2023 Jul 28. PMID: 37493413. 3: Zhang H, Wu M, Hu Y, Li C, Zheng W, Liu J, Li X, Zhu X, Ding Y. Pharmacokinetics and pharmacodynamics of MT-1207, a novel multitarget blocker of α1 receptor, 5-HT2A receptor, and calcium channel, in healthy subjects. Expert Opin Investig Drugs. 2021 Mar;30(3):271-278. doi: 10.1080/13543784.2021.1887137. Epub 2021 Mar 3. PMID: 33560891. 4: Vrettos NN, Wang P, Zhou Y, Roberts CJ, Xu J, Yao H, Zhu Z. In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207. Pharm Dev Technol. 2021 Mar;26(3):349-361. doi: 10.1080/10837450.2021.1872087. Epub 2021 Jan 13. PMID: 33430679. 5: Wang P, Zhu H, Tian JS, Zhu W, Xu S, Yao H, Liu J, Zhu Z, Miao CY, Xu J. Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension. J Med Chem. 2024 Jul 5. doi: 10.1021/acs.jmedchem.4c00626. Epub ahead of print. PMID: 38968440.